Circularity Healthcare | Top Diabetes care Solution Company 2018

MedTech Outlook Magazine

Circularity Healthcare
Improving Blood Flow with Transdermal Technology

Technological innovations are bringing about a paradigm shift in the healthcare arena. Transdermal drug delivery systems—the next big breakthrough in medicine—are increasing in popularity due to the demand for painless drug delivery. In the light of this, Circularity Healthcare, a forward-thinking biotech company based in Pasadena, CA, has emerged as a trailblazer in the space. A front-runner in circulatory health and non-invasive drug delivery technologies, Circularity is on the path to change the standard of care and help improve lives by developing, manufacturing, and marketing wellness, medical device, consumer health, and pharmaceutical products.

Norbert Kiss, president and CEO of Circularity, says, “We believe people should have access to a single medical device that solves a majority of the short- and long-term health issues quickly and without pain.” This led the company to develop a first-of-its-kind biotech solution—D’OXYVA (deoxyhemoglobin vasodilator)—a non-irritating, painless, microcirculatory solution that improves blood flow, which subsequently leads to faster healing of wounds. “Our solution provides a gentle vapor of supersaturated CO2 and water that acts as a catalyst for the body to heal and improve itself,” affirms Dr. Paul Kirkitelos, CFO and business development officer of Circularity. D’OXYVA has been reviewed, clinically studied, and used by some of the prestigious healthcare institutions around the world.

Evidence from years of several highly successful clinical trials indicate that D’OXYVA could help significantly lower the risk of diabetes and cardiovascular complications; improve athletic performance, stamina, and sleep quality; and aid in maintaining skin health. “The solution has also recorded instant and sustained improvements in the autonomic nervous system (ANS), enhanced tissue perfusion, and superior blood macro- and micro-circulation,” adds Dr. Kirkitelos. D’OXYVA is delivered via a patented non-invasive transdermal delivery system—a small, portable, handheld device—and each application takes only five minutes.

D’OXYVA is a non-irritating, painless, microcirculatory solution that improves blood flow, which subsequently leads to faster healing of wounds


The supersaturated medical vapor produced by the system can be administered either by inserting the thumb into the device or gently spraying it on the skin.

“Patients that used D’OXYVA reported quicker wound treatments, lower instances of pain and infection, and faster recovery from trauma,” states Dr. Kirkitelos. Supporting this statement, he cites a case study involving a 62-year-old patient experiencing neuropathic pain, high blood pressure, and diabetic and cardiovascular complications. Due to his severe health conditions, the patient developed open wounds in the lower extremities of his body, which slowly spread and became chronic. Doctors tried every possible solution to cure the patient but were unsuccessful. Stepping into the picture, Circularity provided the patient with D’OXYVA. After using it two times a day for a couple of weeks, the patient was able to walk, his blood pressure reduced by 20-25 points, and all of his wounds healed completely. “This is just one example of how our solution accelerates the treatment of wounds,” replies Dr. Kirkitelos.

Over the years, Circularity has garnered massive consumer and client bases across the U.S., European, and Asian markets. The company also works with pharmaceutical gas providers such as Airgas—the largest producer of FDA-approved (USP) pharma-CO2—to bolster Circularity’s global growth. “The partnership allows Circularity to launch D’OXYVA in hospitals across the U.S. and many other countries,” adds Dr. Kirkitelos. In the days to come, the company is preparing to roll out its product in the Indian market. “We are also set to start clinical trials at leading U.S. research universities under contract, to demonstrate the potential of our solution in rapidly improving bone healing for patients suffering from osteoarthritis,” concludes Kiss. The company is focused on changing the standard of care and improving the dynamics of how the drug is delivered.

Top 10 Diabetes care Solution Companies - 2018

Company
Circularity Healthcare

Management
Norbert Kiss, President & CEO and Dr. Paul Kirkitelos, CFO & Business Development Officer

Description
An emerging biotech pioneer in proprietary circulatory health and non-invasive drug delivery technologies

Circularity Healthcare News

D'OXYVA Launches New At-Home Study to Connect More People With Revolutionary Medical Technology

D'OXYVA is thrilled to launch its nationwide at-home safety and efficacy study, open to participants across the U.S.
LOS ANGELES - Circularity Healthcare, maker of D'OXYVA, announced the launch of a nationwide at-home safety and efficacy study open to participants from across the United States. D'OXYVA, a non-invasive, low-risk regenerative technology, has started enrolling participants suffering from underlying chronic conditions such as severe cardiovascular, diabetic, neurological conditions, and chronic pain, following positive results from similar pivotal trials.
"We have always felt that we needed definitive data on chronic conditions," said Gary Goodman BS, BS, RN, lead principal investigator of the study. "As such, we are conducting this at-home safety and efficacy study and are looking to recruit people with various backgrounds who would benefit from D'OXYVA to target the autonomic nervous system rapidly and address chronic conditions to boost blood flow and tissue oxygenation. Allowing patients from across the U.S. to take part expands our data collection."
D'OXYVA's cutting-edge transdermal delivery system significantly improves microcirculation, tissue perfusion, and autonomic nervous system functions. The extensive, decade-long clinical research has produced high success rates, resulting in powerful results. Additionally, zero adverse events have been reported with over 90 percent of daily users getting relief within 2-4 weeks. D'OXYVA addressed the demand for innovative technologies that cater to pressing unmet medical needs across a spectrum of chronic conditions.
The ongoing study can be completed from anywhere without visiting the private clinic. It will demonstrate how private clinics can administer D'OXYVA (deoxyhemoglobin vasodilator) technology for various patients at home. Participants will pay a discounted price for D'OXYVA and will be provided with diagnostic tools for free with the purchase of each product bundle by the clinic as needed. Additionally, results will be analyzed and reported monthly to the private clinic.
"As a registered nurse, my primary responsibility is to advocate for all individuals and this study allows me and other RNs to do so nationwide," said Goodman. "We serve as intermediaries among patients, physicians, and healthcare providers, so the RN role in this at-home study is critical. We are championing their health by encouraging our eligible patients to participate in the study making a substantial impact on their well-being."